Evidence map›Paper›PMID 36530866›Full record

ArticleFrontiers in medicine2022

In vitro model for investigating aerosol dispersion in a simulated COVID-19 patient during high-flow nasal cannula treatment.

James A McGrath, Andrew O'Sullivan, Mary Joyce, Miriam A Byrne, Jie Li, James B Fink, Ronan MacLoughlin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 2 countries.

James A McGrathDepartment of Physics, School of Natural Science, Ryan Institute's Centre for Climate & Air Pollution Studies, University of Galway, Galway, Ireland.
Andrew O'SullivanResearch & Development, Science & Emerging Technologies, Aerogen Limited, Galway, Ireland.
Mary JoyceResearch & Development, Science & Emerging Technologies, Aerogen Limited, Galway, Ireland.
Miriam A ByrneDepartment of Physics, School of Natural Science, Ryan Institute's Centre for Climate & Air Pollution Studies, University of Galway, Galway, Ireland.
Jie LiDivision of Respiratory Care, Department of Cardiopulmonary Sciences, Rush University Medical Center, Chicago, IL, United States.
James B FinkAerogen Pharma Corporation, San Mateo, CA, United States.
Ronan MacLoughlinResearch & Development, Science & Emerging Technologies, Aerogen Limited, Galway, Ireland.
Aerogen (Ireland) · IEOllscoil na Gaillimhe – University of Galway · IERoyal College of Surgeons in Ireland · IERush University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The use of high-flow nasal cannula in the treatment of COVID-19 infected patients has proven to be a valuable treatment option to improve oxygenation. Early in the pandemic, there were concerns for the degree of risk of disease transmission to health care workers utilizing these treatments that are considered aerosol generating procedures. This study developed an

Indexed as

bioaerosolCOVID-19dispersionexposurefacemaskhigh-flow nasal cannulainfectious diseasesurgical mask

Identifiers

PMID36530866
PMCPMC9751314
OpenAlexW4311047871

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.